NCT04345900: A trial that was reported late by BeyondSpring Pharmaceuticals Inc.
This trial has reported, although it was 855 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04345900 |
|---|---|
| Title | A Phase 2, Multicenter, Randomized Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 5, 2017 |
| Completion date | March 20, 2018 |
| Required reporting date | March 20, 2019, midnight |
| Actual reporting date | July 22, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 855 |